SEC Company Response from Jasper Therapeutics, Inc. (JSPR, JSPRW) (CIK 0001788028) (JSPR) — Nov 18, 2019
Jasper Therapeutics, Inc. (JSPR, JSPRW) (CIK 0001788028)
Date: Nov. 18, 2019 · CIK: 0001788028 · Accession: 0001213900-19-023831
AI Filing Summary & Sentiment
File numbers found in text: 333-234324
Letter
VIA EDGAR Division of Corporation Finance File No. 333-234324 Acceleration Request Requested Date: November 19, 2019 Requested Time: 4:00 p.m. Eastern Time
Re: Amplitude Healthcare Acquisition Corporation
Dear Ms. Block:
In accordance with Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned hereby joins the request of Amplitude Healthcare Acquisition Corporation that the effectiveness for the above-captioned Registration Statement on Form S-1 (as amended through the date hereof) filed under the Securities Act be accelerated by the Securities and Exchange Commission (the “Commission”) to 4:00 p.m. Eastern Time, on November 19, 2019, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Ellenoff Grossman & Schole LLP, request by telephone that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act, we wish to advise you that we have carried out the following distribution of the Company’s preliminary prospectus dated November 8, 2019:
i. Dates of distribution: November 11, 2019 through the date hereof
ii. Number of prospective underwriters to which the preliminary prospectus was furnished: 0
iii. Number of preliminary prospectuses furnished to investors: approximately 270
iv. Number of preliminary prospectuses furnished to underwriters, dealers, institutions and others: approximately 150
We, the undersigned, have complied and will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Remainder of page intentionally left blank]
Very truly yours,
BMO Capital Markets Corp.
Show Raw Text
CORRESP
1
filename1.htm
November 18, 2019
VIA EDGAR
Ms. Susan Block
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Amplitude Healthcare Acquisition Corporation
Registration Statement on Form S-1
File No. 333-234324
Acceleration Request
Requested Date:
November 19, 2019
Requested Time:
4:00 p.m. Eastern Time
Dear Ms. Block:
In accordance with Rule 461 of the General
Rules and Regulations under the Securities Act of 1933, as amended (the “Securities Act”), the undersigned
hereby joins the request of Amplitude Healthcare Acquisition Corporation that the effectiveness for the above-captioned Registration
Statement on Form S-1 (as amended through the date hereof) filed under the Securities Act be accelerated by the Securities and
Exchange Commission (the “Commission”) to 4:00 p.m. Eastern Time, on November 19, 2019, or as soon thereafter
as practicable, or at such other time as the Company or its outside counsel, Ellenoff Grossman & Schole LLP, request by telephone
that such Registration Statement be declared effective.
Pursuant to Rule 460 under the Act,
we wish to advise you that we have carried out the following distribution of the Company’s preliminary prospectus dated November
8, 2019:
i. Dates of distribution: November 11, 2019 through the date hereof
ii. Number of prospective underwriters to which the preliminary prospectus was furnished: 0
iii. Number of preliminary prospectuses furnished to investors: approximately 270
iv. Number of preliminary prospectuses furnished to underwriters, dealers, institutions and others:
approximately 150
We, the undersigned, have complied and
will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[Remainder of page intentionally
left blank]
Very truly yours,
BMO Capital Markets Corp.
SVB Leerink LLC
as Underwriters
BMO CAPITAL MARKETS CORP.
By:
/s/ Eric Benedict
Name:
Eric Benedict
Title:
Group Head, ECM
SVB LEERINK LLC
By:
/s/ Byron T. Webster
Name:
Byron T. Webster
Title:
Managing Director